Dapagliflozin to Prevent Atrial Fibrillation Recurrence After Transcatheter Pulmonary Venous Isolation.

NCT04780438 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

UNKNOWN

Status

350

Enrollment

OTHER

Sponsor class

Conditions

Atrial Fibrillation Recurrent
Pulmonary Venous Isolation
Catheter Ablation
Sodium-glucose Co-transporter 2 Inhibitors

Interventions

DRUG: Dapagliflozin
DRUG: Placebo

Sponsor

G.Gennimatas General Hospital

Collaborators

[object Object]